New Study Finds Limited Documentation of Cost Discussions With Patients Newly Diagnosed With Advanced Cancer

A new study by researchers at the American Cancer Society and the National Cancer Institute, shows only about a quarter of individuals newly diagnosed with advanced cancers had documented physician discussions about costs of care, which may hinder identifying patient needs and tracking outcomes of referrals for assistance.

MD Anderson Research Highlights for April 19, 2023

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

ADAURA Trial Results Provide New Hope for Patients with Early-Stage Non-Small Cell Lung Cancer

Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years. The new results also indicated that the use of osimertinib reduced the risk of disease recurrence in the brain and spinal cord.

NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects, in Collaboration with AstraZeneca

The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer in collaboration with AstraZeneca.

Yale Cancer Center Study Shows New Drug Combinations Improve Outcomes for Patients with Advanced Lung Cancer

New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer.

Yale Cancer Center Perspective Highlights New Advances for NSCLC

A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC). The goal of the study is to provide views on how basic science advances will impact clinical research areas to help influence how NSCLC will be managed over the coming decade.

Roswell Park Researchers Identify New Biomarker of Response to Checkpoint Inhibitors

A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy. This discovery, published today in the journal Nature Communications, is not only an important step forward in lung cancer treatment, but also has implications for other malignancies, according to lead author Fumito Ito, MD, PhD, FACS.

Exploring Autophagy as a Therapeutic Strategy against Frequent Mutations in Non-Small Cell Lung Cancer

Rutgers Cancer Institute of New Jersey expert investigates the role of a cellular survival mechanism known as autophagy in the formation of tumors driven by mutations in tumor suppressors known as LKB1 and oncogene KRAS.

Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung Cancer

The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer, according to a new study led by Yale Cancer Center researchers.

Study Reinforces Benefit Using Targeted Therapy for Early Stage NSCLC

According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.

Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC

According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.

Yale Cancer Center Study Shows Long-Term Survival Benefit for Certain Patients with Advanced Lung Cancer

According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).

Addition of Immunotherapy to Standard Treatment for Advanced Stage Non-Small Cell Lung Cancer is Safe and Tolerable as First-Line Therapy

Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer (NSCLC).

Yale Cancer Center researchers show adding radiation after immunotherapy improves survival time for patients with advanced lung cancer

The results of a phase II clinical trial by Yale Cancer Center (YCC) researchers show adding high-dose radiation after immunotherapy stops working increases survival time for patients with metastatic non-small-cell lung cancer (NSCLC).

Yale Cancer Center researchers show adding radiation after immunotherapy improves survival time for patients with advanced lung cancer

The results of a phase II clinical trial by Yale Cancer Center (YCC) researchers show adding high-dose radiation after immunotherapy stops working increases survival time for patients with metastatic non-small-cell lung cancer (NSCLC).